D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
D-Cycloserine, known from tuberculosis therapy, has been widely introduced to neuropsychiatric studies, since its central active mechanism as a partial NMDA-agonist has been found. In this review, we evaluate its therapeutic potential in neuropsychological disorders and discuss its pitfalls in terms of dosing and application frequency as well as its safety in low-dose therapy. Therefore, we identified 91 clinical trials by performing a Medline search. We demonstrate in part preliminary but increasing evidence that D-cycloserine may be effective in various psychiatric diseases, including schizophrenia, anxiety disorders, addiction, eating disorders, major depression, and autism as well as in neurological diseases, including dementia, Alzheimer's disease, and spinocerebellar degeneration. D-Cycloserine in low-dose therapy is safe, but there is still a need for new drugs with higher specificity to the different N-methyl-D-aspartate-receptor subunits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“At low doses (<100 mg/day), DCS acts as a functional NMDA receptor antagonist, whereas relatively higher doses (>750 mg/day) accelerate glycine site NMDA receptor potentiation and produce DCS’s antidepressant and anxiolytic effects [168].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [168]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [168]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goodman & Gilman's The Pharmacological Basis of Therapeutics
Brunton, L. L. (1985) · Cited by 7,321
Goodman and Gilman's the Pharmacological Basis of Therapeutics
Stigelman, W. H., & Pharm, D. (1986) · Military Medicine · doi:10.1093/milmed/151.1.386 · Cited by 6,782
Negative Symptoms in Schizophrenia: Definition and Reliability
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070020005 · Cited by 2,247
Walker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Applying extinction research and theory to cue‐exposure addiction treatments
Conklin, C. A., & Tiffany, S. T. (2002) · Addiction · doi:10.1046/j.1360-0443.2002.00014.x · Cited by 701
Danysz, W., & Parsons, C. G. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01382-6 · Cited by 649
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy
Norberg, M. M., Krystal, J. H., & Tolin, D. F. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.012 · Cited by 510 · cited 3×
“A huge meta-analysis (Norberg et al., 2008) of data from human and animal studies showed a significant, though moderate, positive effect of DCS on exposure therapy/ fear extinction.”
BackgroundInfluentialEffects of D-Cycloserine on Extinction: Translation From Preclinical to Clinical Work
Davis, M., Ressler, K., Rothbaum, B. O., & Richardson, R. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.03.084 · Cited by 498 · cited 1×
“The mechanism of action of DCS might change or even reverse under conditions with great stress and might be due to different surrounding neurotransmitter concentrations (Hood et al., 1989; Watson et al., 1990; Sheinin et al., 2001; Davis et al., 2006).”
BackgroundGoff, D. C., Tsai, G., Levitt, J., Amico, E., Manoach, D., Schoenfeld, D. A., Hayden, D. L., McCarley, R., & Coyle, J. T. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.1.21 · Cited by 436
Glycine binding primes NMDA receptor internalization
Nong, Y., Huang, Y.-Q., Ju, W., Kalia, L. V., Ahmadian, G., Wang, Y. T., & Salter, M. W. (2003) · Nature · doi:10.1038/nature01497 · Cited by 429
Cited by
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
Hansen, K. B., Wollmuth, L. P., Bowie, D., Furukawa, H., Menniti, F. S., Sobolevsky, A. I., Swanson, G. T., Swanger, S. A., Greger, I. H., Nakagawa, T., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000131 · Cited by 686
Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00876 · Cited by 409
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
“Studies using transcranial direct current stimulation (tDCS) have shown that DCS modulates neuroplasticity through long-term potentiation via action on cortical NMDA receptors in humans [168,169].”
BackgroundSebih, F., Rousset, M., Bellahouel, S., Rolland, M., de Jesus Ferreira, M. C., Guiramand, J., Cohen-Solal, C., Barbanel, G., Cens, T., Abouazza, M., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00036 · Cited by 24
Donello, J. E., McIntyre, R. S., Pickel, D. B., & Stahl, S. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020157 · Cited by 15
“Sarcosine is an orthosteric glycine site-dependent NMDAR agonist, and D-cycloserine is an orthosteric glycine site NMDAR partial agonist [64,65].”
Metadata
- Authors
- Schade, S., & Paulus, W.
- Affiliations
- Universitätsmedizin Göttingen (DE)
- Corresponding author
- Schade, Sebastian
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-09-12
- Volume
- 19
- Issue
- 4
- Pages
- pyv102
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC4851259
- OpenAlex
- W2336203720
- Cited by
- 135
- References
- 79
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 10 · 2023: 18 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 14 · 2018: 8 · 2017: 7 · 2016: 7 · 2015: 1
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- GRO (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- D-cycloserine, NMDA receptor partial agonist, schizophrenia, anxiety disorders, addiction, eating disorders, major depressive disorder, autism spectrum disorder, dementia, Alzheimer's disease, spinocerebellar degeneration, dosing and administration, neuropsychiatric disorders
- MeSH terms
- Animals, Mental Disorders, Cycloserine, Humans, Nervous System Diseases, Psychotropic Drugs, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review. https://app.cochat.ai/papers/10.1093/ijnp/pyv102
- The paper
- Schade, S., & Paulus, W. (2016). D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review. International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyv102
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.